Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-weekly insulin icodec versus once-daily insulin degludec in insulin-naive adults with type 2 diabetes
2020-000472-37Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Insulin icodec once weekly with Insulin degludec once daily (2 arms). Primary endpoint: Change in HbA1c. Started Oct 2020; status: completed.
02
Drugs
insulin icodecinsulin degludec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2020-000472-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000472-37.